News

Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
BioSpace10h
5 Oral Obesity Drugs Challenging Lilly’s Orforglipron
Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.
Eli Lilly’s Weight Loss Pill Doesn’t Work as Well as Investors Hoped. The Obesity Trade Is Wavering Again.
Sales grew 38% year over year, driven by volume growth from weight-loss and diabetes drugs Zepbound and Mounjaro, Lilly said.
Eli Lilly Q2 Earnings: Ignore Oral Weight Loss Bombshell, This Is A Buy The Dip Moment
Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...
Wegovy maker Novo Nordisk warns on continued copycat-drug challenge as new CEO readied
Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...
Novo’s Growth Sputters as US Competition Dents Obesity Sales
Novo Nordisk A/S’s sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly & Co. in ...